Holen Sie sich die Stockscreener-App
46.11
0.07%
0.03
Schlusskurs vom Vortag:
$46.08
Offen:
$46.18
24-Stunden-Volumen:
7.00M
Relative Volume:
1.52
Marktkapitalisierung:
$3.47B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-275.16M
KGV:
-11.85
EPS:
-3.89
Netto-Cashflow:
$-221.15M
1W Leistung:
-0.32%
1M Leistung:
+22.18%
6M Leistung:
+26.50%
1J Leistung:
+2.99%
1-Tages-Spanne:
$46.09
$46.21
1-Wochen-Bereich:
$46.05
$46.31
52-Wochen-Spanne:
$28.21
$62.00
Springworks Therapeutics Inc Stock (SWTX) Company Profile
Firmenname
Springworks Therapeutics Inc
Sektor
Branche
Telefon
203-883-9490
Adresse
100 WASHINGTON BOULEVARD, STAMFORD, CT
Vergleichen Sie SWTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SWTX
Springworks Therapeutics Inc
|
46.11 | 3.48B | 0 | -275.16M | -221.15M | -3.89 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Springworks Therapeutics Inc Stock (SWTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-20 | Eingeleitet | Evercore ISI | Outperform |
| 2024-02-05 | Eingeleitet | Guggenheim | Buy |
| 2022-12-01 | Eingeleitet | BofA Securities | Buy |
| 2021-01-19 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-29 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-05 | Eingeleitet | Barclays | Overweight |
| 2020-03-19 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-03-04 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-01-21 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-10-08 | Eingeleitet | Cowen | Outperform |
| 2019-10-08 | Eingeleitet | Goldman | Buy |
| 2019-10-08 | Eingeleitet | JP Morgan | Overweight |
| 2019-10-08 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Springworks Therapeutics Inc Aktie (SWTX) Neueste Nachrichten
Ameriprise Financial Inc. Acquires 173,222 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Northern Trust Corp Has $23.69 Million Stock Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Its Investigation Into The Merger - Benzinga
J. Goldman & Co LP Has $1.93 Million Stock Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Sold by D. E. Shaw & Co. Inc. - MarketBeat
Patient Square Capital LP Invests $3.37 Million in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Merck, SpringWorks submitted German antitrust filing May 8, US form May 14 - MLex
Algert Global LLC Purchases Shares of 35,340 SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Neurofibromatosis Type 1 Market Set to Witness Significant Growth During the Study Period (2020–2034) Driven by Advances in Treatment | DelveInsight - GlobeNewswire Inc.
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Sold by Orbimed Advisors LLC - MarketBeat
(SWTX) On The My Stocks Page - news.stocktradersdaily.com
SpringWorks reports annual meeting results - Investing.com Australia
SpringWorks reports annual meeting results By Investing.com - Investing.com Nigeria
Springworks Therapeutics Holds Annual Stockholders Meeting - TipRanks
Integral Health Asset Management LLC Buys Shares of 100,000 SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
SpringWorks Therapeutics (NASDAQ:SWTX) Given "Neutral" Rating at Guggenheim - MarketBeat
Deals In Depth: April 2025 - insights.citeline.com
Balyasny Asset Management L.P. Invests $3.10 Million in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
SpringWorks Therapeutics (NASDAQ:SWTX) Given “Neutral” Rating at Guggenheim - Defense World
Dimensional Fund Advisors LP Lowers Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Duquesne Family Office LLC Grows Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
SpringWorks Therapeutics (SWTX) Rating and Price Target Update b - GuruFocus
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Sold by Deep Track Capital LP - MarketBeat
Decoding SpringWorks Therapeutics Inc (SWTX): A Strategic SWOT I - GuruFocus
First Trust Advisors LP Buys 2,115 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - Defense World
The Manufacturers Life Insurance Company Acquires 122,128 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
SpringWorks Therapeutics (SWTX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
SpringWorks Therapeutics: Q1 Earnings Snapshot - CT Insider
ArrowMark Colorado Holdings LLC Boosts Stock Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
SpringWorks Therapeutics Retail Chatter Spikes As Germany’s Merck Confirms Late-Stage Talks For $3.5B Buyout - MSN
Boxer Capital Management LLC Buys New Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Ally Bridge Group NY LLC Has $1.98 Million Stock Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Dimensional Fund Advisors LP Lowers Stock Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - Defense World
SpringWorks Therapeutics (NASDAQ:SWTX) Cut to Hold at Evercore ISI - MarketBeat
SpringWorks Therapeutics (NASDAQ:SWTX) Earns "Neutral" Rating from HC Wainwright - MarketBeat
TD Cowen Downgrades SpringWorks Therapeutics (SWTX) - MSN
Soros Fund Management LLC Purchases 41,149 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
TD Cowen Reaffirms Hold Rating for SpringWorks Therapeutics (NASDAQ:SWTX) - MarketBeat
Merck KGaA (MKGAF) to Acquire SpringWorks Therapeutics for $3.9 Billion - GuruFocus
(SWTX) Trading Report - news.stocktradersdaily.com
Merck KGaA’s $3.9 Billion Springworks Deal to Boost US Presence - MSN
SpringWorks Therapeutics (NASDAQ:SWTX) Shares Gap UpHere's Why - MarketBeat
Finanzdaten der Springworks Therapeutics Inc-Aktie (SWTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.54%
7.58%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):